Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants

The highly selective, covalent Bruton’s tyrosine kinase inhibitor evobrutinib is under investigation for treatment of patients with multiple sclerosis (MS). Early clinical studies in healthy participants and patients with relapsing MS indicated that evobrutinib is well‐tolerated and effective. We un...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheible, Holger, Dyroff, Martin, Seithel‐Keuth, Annick, Harrison‐Moench, Eleanor, Mammasse, Nadra, Port, Andreas, Bachmann, Angelika, Dong, Jennifer, van Lier, Jan Jaap, Tracewell, William, Mitchell, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604242/
https://www.ncbi.nlm.nih.gov/pubmed/34374206
http://dx.doi.org/10.1111/cts.13108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604242/
https://www.ncbi.nlm.nih.gov/pubmed/34374206
http://dx.doi.org/10.1111/cts.13108

Ejemplares similares